Labcorp raises full year outlook after quarterly beat
Labcorp raised its annual profit forecast to a range of $17.70 to $18.35 per share. Strong demand for diagnostic testing helped the company beat estimates.
Xurve View
洞察:
Xurve View
LABCORP HOLDINGS INC raised its 2026 revenue guidance to a $14.80 billion ceiling after first-quarter profit of $4.25 per share beat expectations. The laboratory operator increased its adjusted EPS outlook to $17.70-$18.35, surpassing the $17.87 average estimate from LSEG-compiled data. Steady diagnostic demand and hospital lab management deals are offsetting a slowdown in biotech spending within the drug development unit.
